Pfizer Inc. (PFE)
Can This Beaten-Down Stock Bounce Back in 2025?
In 2022, pharmaceutical giant Pfizer (PFE -2.37%) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price.
Is Pfizer Stock a Buy?
Pharmaceutical giant Pfizer (PFE 1.29%) is trading near its lowest price in over a decade.
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $26.64, indicating a +1.29% shift from the previous trading day.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer CEO: Americans can expect radical change from this upcoming Trump administration
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S. president, becoming the second to serve two non-consecutive terms.
3 Upcoming Dividend Increases
This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of 8.7%. My strategy focuses on buying, holding, and adding companies that consistently increase dividends and outperform benchmarks. I use data from U.S. Dividend Champions and NASDAQ to guide my decisions. I prioritize stocks with strong historical performance and dividend growth, comparing them against benchmarks like SCHD and RNP for non-REITs and REITs, respectively.
What To Expect From PFE Stock In 2025?
Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), Pfizer's stock performance has been muted.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each, reduced Pfizer's ownership in the British consumer healthcare giant to 7.3%.
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion.
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer (PFE) reachead $26.41 at the closing of the latest trading day, reflecting a -1.46% change compared to its last close.
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fund, SAC Capital Management.
